Notable healthcare headlines for the week: Eli Lilly, Hims & Hers Health, and Merck in focus
Seeking Alpha News (Sun, 16-Aug 9:05 AM ET)
Cencora Announces Resignation of Board Member Lorence Kim
TipRanks (Fri, 14-Aug 5:05 PM ET)
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Cencora (COR)
TipRanks (Fri, 14-Aug 4:40 AM ET)
Cencora (COR) Gets a Buy from Evercore ISI
TipRanks (Thu, 13-Aug 10:15 AM ET)
Bank of America Securities Remains a Hold on Cencora (COR)
TipRanks (Thu, 13-Aug 6:57 AM ET)
Cencora dips on loss of some Walgreens business
Seeking Alpha News (Wed, 12-Aug 1:20 PM ET)
Cencora Reaffirms 2026 EPS Outlook Amid Walgreens Shift
TipRanks (Wed, 12-Aug 12:57 PM ET)
Cencora Boosts Earnings Outlook with Broad-Based Profit Growth and Strong Segment Performance
Market Chameleon (Wed, 5-Aug 4:11 AM ET)
Cencora Reports Fiscal 2026 Third Quarter Results
Business Wire (Wed, 5-Aug 6:30 AM ET)
Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
Business Wire (Wed, 1-Jul 4:30 PM ET)
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Cencora trades on the NYSE stock market under the symbol COR.
As of August 17, 2026, COR stock price climbed to $316.52 with 100,486 million shares trading.
COR has a beta of -0.07, meaning it tends to be less sensitive to market movements. COR has a correlation of 0.00 to the broad based SPY ETF.
COR has a market cap of $60.40 billion. This is considered a Large Cap stock.
Last quarter Cencora reported $85 billion in Revenue and $4.48 earnings per share. This beat revenue expectation by $407 million and exceeded earnings estimates by $.12.
The top ETF exchange traded funds that COR belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
COR has underperformed the market in the last year with a price return of +8.5% while the SPY ETF gained +21.4%. However, in the short term, COR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +22.0% vs +3.9% return in SPY. But in the last 2 weeks, COR shares have been beat by the market, returning +1.9% compared to an SPY return of +3.8%.
COR support price is $308.00 and resistance is $319.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COR shares will trade within this expected range on the day.